In conclusion, using the large TROG 03.04 RADAR clinical trial cohort, our study has clarified the clinical significance of CCR2 and CCL2 protein expression in locally advanced prostate cancer by showing that despite being expressed in prostate tumours, CCR2 and CCL2 have no prognostic value in the disease. The gene discussed is CCR2; the disease is prostate carcinoma.